期刊文献+

胰岛素和亚硒酸钠最佳配比组方研究 被引量:2

Study on Optimal Combination Ratio of Insulin and Sodium Selenite
下载PDF
导出
摘要 目的确定普通胰岛素与亚硒酸钠降血糖作用的最佳组方配比。方法采用小剂量链脲佐菌素腹腔注射联合高糖高脂饲养的大鼠模型,以血糖降低百分率为考察指标,根据权重配方法设不同配比组方6组,分析结果得出最佳理论配比,并进一步做确证性试验考察二者的相互关系。结果胰岛素与亚硒酸钠对血糖的控制为协同作用,二者比例为1 U∶5μg时可显著降低血糖。结论胰岛素和亚硒酸钠的最佳配比为1 U∶5μg。 Objective To determine the optimal combination ratio of regular insulin and sodium selenite for reducing blood glu- cose. Methods High-fat high-glucose diet-induced rats were injected with a low dose of streptozotocin into peritoneal. Decreasing percentage of blood glucose was used as reference index. 6 formulas with different combination ratios were designed according to the weighted modification method. The results were analyzed for obtaining the optimal theoretical combination ratio. Then the further confir- mation test was conducted for investigating the relation between regular insulin and sodium selenite. Results Regular insulin and sodium selenite had the additive effect on blood glucose. When the ratio was 1 U:5 μg,regular insulin and sodium selenite could reduce blood glucose significantly. Conclusion The optimal combination ratio of regular insulin and sodium selenite is 1 U : 5μg.
出处 《中国药业》 CAS 2012年第8期36-37,共2页 China Pharmaceuticals
基金 国家自然科学青年基金 项目编号:30901808 陕西省科技统筹创新工程计划项目 项目编号:2011KTCL03-20
关键词 胰岛素 亚硒酸钠 权重配方法 糖尿病大鼠 血糖 : regular insulin sodium selenite weighted modification method diabetic rat blood glucose.
  • 相关文献

参考文献9

  • 1Lipscombe LL,Hux JE. Trends in diabetes prevalence,incidence,and mortality in Ontario,Canada 1995-2005:a population -based study[J].The Lancet,2007,(9 563):750-756.
  • 2Erbayraktar Z,Yilmaz 0,Artmann AT. Effects of selenium supplementation on antioxidant defense and glucose homeostasis in experimental diabetes mellitus[J].Biological Trace Element Research,2007,(03):217-226.
  • 3Hwang D,Seo S,Kim Y. Selenium acts as an insulin-like molecule for the down-regulation of diabetic symptoms via endoplasmic reticulum stress and insulin signalling proteins in diabetes-induced non -obese diabetic mice[J].Journal of Biosciences,2007,(04):723-735.
  • 4Zheng QS,Sun RY. Quantitative design of drug compatibility by weighted modification method[J].Acta Pharmacologica Sinica,1999,(11):1043-1051.
  • 5郑青山,孙瑞元.药物相互作用动力学分析方法及其CoDrug软件[J].中国临床药理学与治疗学,2002,7(1):81-82. 被引量:16
  • 6陈志扬,郑青山,孙瑞元.大型药理学计算软件DAS的功能介绍[J].中国临床药理学与治疗学,2002,7(6):562-564. 被引量:53
  • 7Stratton IM,Adler Al,Neil HA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study[J].British Medical Journal,2000,(7 258):405-412.doi:10.1136/bmj.321.7258.405.
  • 8Molyneaux LM,Constantino MI,McGill M. Better glyeaemic control and risk reduction of diabetic complications in Type 2 diabetes:comparison with the DCCT[J].Diabetes Research and Clinical Practice,1998,(02):77-83.
  • 9Xu TJ,Yuan BX,Zou YM. The effect of insulin in combination with selenium on blood glucose and GLUT4 expression in the cardiac muscle of streptozotocin-induced diabetic rats[J].Fundamental and Clinical Pharmacology,2010,(02):199-204.

二级参考文献12

  • 1倪宗瓒.卫生统计学(第4版)[M].北京:人民卫生出版社,2000..
  • 2郑青山,孙瑞元. 药物联用定量分析方法研究进展[A]. 见:金正均,王永铭,苏定冯. 主编. 药理学进展 (1998)[M]. 第1版. 北京:科学出版社,1998:148
  • 3郑青山,郑青山. 药物相互作用动力学软件(CoDrug)用户手册[Z]. 2001:1-20
  • 4Zheng QS, Sun RY. Quantitative analysis of drug compatibility by weighed modification method[J]. Acta Pharmacol Sin 1999;20:1043-51
  • 5Zheng QS, Sun RY. Analysis of multidrug effects by parameter method[J]. Acta Pharmacol Sin 1998;19:232-7
  • 6Zheng QS, Sun RY. Analysis of drug interactions in combined therapy by reflection method[J]. Acta Pharmacol Sin 2000;21:183-87
  • 7Zheng QS, Gui CQ, Sun RY. A method of comprehensive evaluation of multiple response variables in drug interaction[J]. Indian J Pharmacol 2001; 33: 445-7
  • 8Berenbaum MC. What is synergy?[J] Pharmacol Rev 1989;41:93-141
  • 9Loewe S. The problem of synergism and antagonism of combined drugs[J]. Arzneimittelforschung 1928;3:285
  • 10Chou TC, Talalay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors[J]. Adv Enzyme Reg 1984;22:27

共引文献67

同被引文献47

引证文献2

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部